Experience with fulvestrant acetate in castration-resistant prostate cancer patients

被引：11

作者：

Gasent Blesa, J. M. ^{[1
]}

Alberola Candel, V. ^{[2
]}

Giner Marco, V. ^{[3
]}

Giner-Bosch, V. ^{[4
]}

Provencio Pulla, M. ^{[5
]}

Laforga Canales, J. B. ^{[6
]}

机构：

[1] Hosp Denia, Dept Med Oncol, Denia, Valencia, Spain

[2] Hosp Arnau Vilanova, Dept Med Oncol, Valencia, Spain

[3] Hosp Sagunt, Dept Med Oncol, Sagunt, Spain

[4] Univ Politecn Valencia, Dept Appl Stat Operat Res & Qual, E-46071 Valencia, Spain

[5] Hosp Univ Puerta de Hierro, Dept Med Oncol, Madrid, Spain

[6] Hosp Denia, Dept Pathol, Denia, Spain

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷 / 05期

关键词：

ANDROGEN RECEPTOR; RETAINS ACTIVITY; DOCETAXEL; BETA;

D O I：

10.1093/annonc/mdq010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1131 / 1132

页数：2

共 10 条

[1] Phase II study of fulvestrant (Faslodex®) in castration resistant prostate cancer [J].

Chadha, Manpreet K. ;

Ashraf, Umeer ;

Lawrence, David ;

Tian, Lili ;

Levine, Ellis ;

Silliman, Carrie ;

Escott, Paul ;

Payne, Valencia ;

Trump, Donald L. .

PROSTATE, 2008, 68 (13) :1461-1466

[2]

DANILA DC, 2008, P AM SOC CLIN ONCOL, V26

[3] ANTIESTROGEN ICI-164,384 REDUCES CELLULAR ESTROGEN-RECEPTOR CONTENT BY INCREASING ITS TURNOVER [J].

DAUVOIS, S ;

DANIELIAN, PS ;

WHITE, R ;

PARKER, MG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (09) :4037-4041

[4] INHIBITION OF ESTROGEN-RECEPTOR DNA-BINDING BY THE PURE ANTIESTROGEN ICI-164,384 APPEARS TO BE MEDIATED BY IMPAIRED RECEPTOR DIMERIZATION [J].

FAWELL, SE ;

WHITE, R ;

HOARE, S ;

SYDENHAM, M ;

PAGE, M ;

PARKER, MG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (17) :6883-6887

[5] Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer [J].

Galsky, M. D. ;

Simon, K. ;

Sonpavde, G. ;

Hutson, T. E. ;

Fleming, M. ;

Kondagunta, G. V. ;

Berry, W. .

ANNALS OF ONCOLOGY, 2009, 20 (05) :965-966

[6]

Lau KM, 2000, CANCER RES, V60, P3175

[7] Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma [J].

Leav, I ;

Lau, KM ;

Adams, JY ;

McNeal, JE ;

Taplin, ME ;

Wang, JF ;

Singh, H ;

Ho, SM .

AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (01) :79-92

[8]

RUMI S, 2006, MOL CANCER THER, V5, P1539

[9] The androgen receptor: a potential target for therapy of prostate cancer [J].

Santos, AF ;

Huang, H ;

Tindall, DJ .

STEROIDS, 2004, 69 (02) :79-85

[10] Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer [J].

Serrate, C. ;

Loriot, Y. ;

Rouge, T. De La Motte ;

Gross-Goupil, M. ;

Massard, C. ;

Escudier, B. ;

Bossi, A. ;

Fizazi, K. .

ANNALS OF ONCOLOGY, 2009, 20 (05) :965-965

← 1 →